Expanding the Horizon of Immuno-Oncology
NeoImmuneTech is expanding the horizon of Immuno-Oncology and enhancing immunity to infectious diseases.
Diverse pipeline spanning multiple oncologic and lymphopenia-related indications
NIT's long-acting IL-7 therapeutics demonstrate safety and preliminary efficacy in ongoing Phase I and II oncology trials, with promising results in non-oncology pipelines. This includes NT-I7 mono therapy, as well as combination therapies with checkpoint inhibitors and CAR-T cells.
Addressing unmet medical needs caused by local or systemic T cell depletion
Unlike other cytokines, Interleukin-7 (IL-7) induces selective expansion of T cells to restore a core component of the immune response. Other T cell–promoting cytokines such as IL-2 and IL-15 only support T cell differentiation, activation, and/or proliferation without driving new development—and they cause cytokine storm when given clinically.
At present, with major clinical trials examining solid tumors, brain cancer, and blood cancer progressing smoothly, we plan to maximize the value of new drug development for the next generation immunotherapy, to be acknowledged by the global market, by giving our best efforts in clinical development and continuing to communicate with the market.
Se Hwan Yang CEO & President NeoImmuneTech, Inc.
Get in touch
Contact us for more information about how we can help you invest in healthcare, biotech, climate tech, or advanced systems.